ASLAN Pharmaceuticals Limited
ASLNNASDAQHealthcare
$0.60
$-0.10(-14.27%)
Market Cap$777122375
P/E Ratio—
52W High$17.04
52W Low$0.475
ASLAN Pharmaceuticals Limited (ASLN) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
ASLN · earnings · updated Jun 9, 2026
Latest Earnings
Q3 FY2024Report Date: Aug 9, 2024EPS Actual
-$0.88
Est. -$3.60 · +75.6%
Revenue
—
Fiscal Period
Q3 FY2024
FY ends December
Report Date
Aug 9, 2024
After Market Close
▲ Beat EPS✓ 1-Quarter EPS Beat Streak
ASLN reports quarterly as a NASDAQ-listed Biotechnology company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
84
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
$1.00
Rev. $1.80B
Days Away84
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.$1.00
Rev. Est.$1.80B
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ▲ Q3 FY2024 | Aug 9, 2024 | -$3.60 | -$0.88 | +75.6% | — | — | — |
| ▼ Q2 FY2024 | Apr 12, 2024 | -$0.61 | -$6.24 | -923.0% | — | — | — |
| ▼ Q1 FY2024 | Mar 29, 2024 | -$0.65 | -$0.78 | -20.0% | — | — | — |
| ▲ Q4 FY2023 | Oct 27, 2023 | -$6.80 | -$4.48 | +34.1% | — | — | — |
| ▲ Q3 FY2023 | Aug 11, 2023 | -$6.96 | -$0.88 | +87.4% | $0.01B | — | — |
| ▼ Q2 FY2023 | Apr 28, 2023 | -$6.40 | -$10.32 | -61.3% | — | — | — |
| ▼ Q1 FY2023 | Mar 24, 2023 | -$7.60 | -$8.32 | -9.5% | — | — | — |
| ▲ Q4 FY2022 | Oct 28, 2022 | -$8.00 | -$6.40 | +20.0% | — | — | — |
Q3 FY2024
Aug 9, 2024Beat
EPS Actual
-$0.88
EPS Est.
-$3.60
EPS Surpr.
+75.6%
Revenue
—
Q2 FY2024
Apr 12, 2024Miss
EPS Actual
-$6.24
EPS Est.
-$0.61
EPS Surpr.
-923.0%
Revenue
—
Q1 FY2024
Mar 29, 2024Miss
EPS Actual
-$0.78
EPS Est.
-$0.65
EPS Surpr.
-20.0%
Revenue
—
Q4 FY2023
Oct 27, 2023Beat
EPS Actual
-$4.48
EPS Est.
-$6.80
EPS Surpr.
+34.1%
Revenue
—
Q3 FY2023
Aug 11, 2023Beat
EPS Actual
-$0.88
EPS Est.
-$6.96
EPS Surpr.
+87.4%
Revenue
$0.01B
Q2 FY2023
Apr 28, 2023Miss
EPS Actual
-$10.32
EPS Est.
-$6.40
EPS Surpr.
-61.3%
Revenue
—
Q1 FY2023
Mar 24, 2023Miss
EPS Actual
-$8.32
EPS Est.
-$7.60
EPS Surpr.
-9.5%
Revenue
—
Q4 FY2022
Oct 28, 2022Beat
EPS Actual
-$6.40
EPS Est.
-$8.00
EPS Surpr.
+20.0%
Revenue
—
Analyst Estimates
Limited analyst coverage (fewer than 3 analysts). Estimates may not reflect market consensus.
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2025 | $-5.04 | $-5.04 | $-5.04 | 1 |
| Q3 FY2025 | $-4.80 | $-4.80 | $-4.80 | 1 |
| Q2 FY2025 | $-4.64 | $-4.64 | $-4.64 | 1 |
| Q1 FY2025 | $-4.40 | $-4.40 | $-4.40 | 1 |
| Q4 FY2024 | $-0.08 | $-0.08 | $-0.08 | 1 |
| Q3 FY2024 | $-0.16 | $-0.16 | $-0.16 | 1 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2025 | $0.0B | $0.0B | $0.0B | 0 |
| Q3 FY2025 | $0.0B | $0.0B | $0.0B | 0 |
| Q2 FY2025 | $0.0B | $0.0B | $0.0B | 0 |
| Q1 FY2025 | $0.0B | $0.0B | $0.0B | 0 |
| Q4 FY2024 | $0.0B | $0.0B | $0.0B | 0 |
| Q3 FY2024 | $0.0B | $0.0B | $0.0B | 0 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| ▲ Q3 FY2024 | Aug 9, 2024 | +75.6% | $0.60 | $0.60 | +0.00% |
| ▼ Q2 FY2024 | Apr 12, 2024 | -923.0% | $4.32 | $4.00 | -7.41% |
| ▼ Q1 FY2024 | Mar 29, 2024 | -20.0% | $4.92 | $4.81 | -2.24% |
| ▲ Q4 FY2023 | Oct 27, 2023 | +34.1% | $9.52 | $8.52 | -10.50% |
| ▲ Q3 FY2023 | Aug 11, 2023 | +87.4% | $17.28 | $17.36 | +0.46% |
| ▼ Q2 FY2023 | Apr 28, 2023 | -61.3% | $34.00 | $33.20 | -2.35% |
| ▼ Q1 FY2023 | Mar 24, 2023 | -9.5% | $22.00 | $23.28 | +5.82% |
| ▲ Q4 FY2022 | Oct 28, 2022 | +20.0% | $15.96 | $16.00 | +0.25% |
Q3 FY2024+0.00%
Report Date
Aug 9, 2024
EPS Beat/Miss
+75.6%
Price Before
$0.60
Price After
$0.60
Q2 FY2024-7.41%
Report Date
Apr 12, 2024
EPS Beat/Miss
-923.0%
Price Before
$4.32
Price After
$4.00
Q1 FY2024-2.24%
Report Date
Mar 29, 2024
EPS Beat/Miss
-20.0%
Price Before
$4.92
Price After
$4.81
Q4 FY2023-10.50%
Report Date
Oct 27, 2023
EPS Beat/Miss
+34.1%
Price Before
$9.52
Price After
$8.52
Q3 FY2023+0.46%
Report Date
Aug 11, 2023
EPS Beat/Miss
+87.4%
Price Before
$17.28
Price After
$17.36
Q2 FY2023-2.35%
Report Date
Apr 28, 2023
EPS Beat/Miss
-61.3%
Price Before
$34.00
Price After
$33.20
Q1 FY2023+5.82%
Report Date
Mar 24, 2023
EPS Beat/Miss
-9.5%
Price Before
$22.00
Price After
$23.28
Q4 FY2022+0.25%
Report Date
Oct 28, 2022
EPS Beat/Miss
+20.0%
Price Before
$15.96
Price After
$16.00
Avg Beat Reaction-2.45%
Avg Miss Reaction-1.54%
Beat Rate4 / 8 quarters
Largest Move-10.50% (Q4 FY2023)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: ASLN ends December
ASLAN Pharmaceuticals Limited (ASLN) most recently reported earnings on August 9, 2024 for Q3 FY2024, posting EPS of $-0.88 — beating the analyst consensus of $-3.60 by +75.6%. The next ASLN earnings date is expected around September 1, 2026.
Each quarter, investors track ASLN earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. ASLN revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
ASLN's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
ASLN earnings · 5 questionsASLAN Pharmaceuticals Limited's next earnings report is expected around September 1, 2026. ASLN typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; ASLN historically reports after market close (AMC).
ASLN earnings datewhen is ASLN earningsASLN next earnings datewhen does ASLN report earningsASLN earnings calendar
▸ Source: FMP · ASLAN Pharmaceuticals Limited SEC filings · US GAAP · ASLAN Pharmaceuticals Limited SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 9, 2026